Verification evidence is still being completed.
PDF / print export
Alentis Therapeutics
Basel, Switzerland
- Verified lead
- Mark Pruzanski
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Fibrosis, Oncology, Antibody Therapeutics, Claudin-1 Biology, and Clinical Development
- Review cycle
- May 2026
- Full address
- Basel, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official ALENTIS contact page confirming the Basel address.
- Editorial note
- Alentis Therapeutics is published because official company materials confirm current leadership, Basel operating address, and a real Claudin-1 therapeutics platform.
Fibrosis, Oncology, Antibody Therapeutics, Claudin-1 Biology, and Clinical Development
Official leadership disclosure, Official Basel address disclosure, Clinical-stage therapeutics platform claim
Alentis Therapeutics is published because official company materials confirm current leadership, Basel operating address, and a real Claudin-1 therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Basel, Switzerland
Alentis Therapeutics
Fibrosis, Oncology, Antibody Therapeutics, Claudin-1 Biology, and Clinical Development · Clinical-stage therapeutics platform
Alentis Therapeutics runs fibrosis drug development, oncology therapeutics programs, and antibody platform development in Basel, Switzerland.
- Lead
- Mark Pruzanski (verified ↗)
- Address
- Basel, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Fibrosis Drug Development · Oncology Therapeutics Programs · Antibody Platform Development
- Founded
- 2019
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Mark Pruzanski
Chief Executive Officer
Full addressBasel, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage therapeutics platform
Basel, Switzerland. Fibrosis, Oncology, Antibody Therapeutics, Claudin-1 Biology, and Clinical Development. Review completed on 22 Mar 2026.
Swiss corporate and clinical-development oversight
Official leadership disclosure, Official Basel address disclosure, Clinical-stage therapeutics platform claim
Fibrosis, Oncology, Antibody Therapeutics, Claudin-1 Biology, and Clinical Development
Alentis Therapeutics is published because official company materials confirm current leadership, Basel operating address, and a real Claudin-1 therapeutics platform.
Editorial note
Alentis Therapeutics is published because official company materials confirm current leadership, Basel operating address, and a real Claudin-1 therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Fibrosis Drug Development
Oncology Therapeutics Programs
Antibody Platform Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Antibody development workflow
Clinical program systems
Therapeutics platform infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Alentis Therapeutics located?
- Alentis Therapeutics operates from Basel, Switzerland, Basel, Switzerland.
- Who runs Alentis Therapeutics?
- Alentis Therapeutics is led by Mark Pruzanski, Chief Executive Officer. Verified 22 Mar 2026.
- What does Alentis Therapeutics do?
- Alentis Therapeutics runs fibrosis drug development, oncology therapeutics programs, and antibody platform development in Basel, Switzerland. Core capabilities: Fibrosis Drug Development, Oncology Therapeutics Programs, Antibody Platform Development.
Editorial context
Related technical briefs
Briefs that name Basel as a covered market or city.